Cravath, Davis Polk Lead on Latest Big Drug Buy

, The Am Law Daily

   | 0 Comments

In its biggest deal since its $46.8 billion takeover of Genentech in 2009, Swiss drug giant Roche has turned to Davis Polk & Wardwell for counsel on its $8.3 billion buy of suburban San Francisco-based lung disease drug developer InterMune, which is being advised by Cravath, Swaine & Moore and a Chicago IP boutique.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202668020591

Thank you!

This article's comments will be reviewed.